Historical Controls For Epilepsy Studies To Be Considered By Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline's Lamictal XR and several drugs in the pipeline could see their quest for monotherapy indications affected by what the Peripheral and Central Nervous System Drugs Advisory Committee decides.